Opaleye Management Inc. Morpho Sys Ag Transaction History

Opaleye Management Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$8.6 - $18.18 $688,000 - $1.45 Million	-80,000 Reduced 55.17%	65,000 $1.18 Million
Q4 2023 Feb 14, 2024	SELL	$4.55 - $9.9 $4.84 Million - $10.5 Million	-1,064,380 Reduced 88.01%	145,000 $1.44 Million
Q2 2023 Aug 14, 2023	BUY	$3.95 - $7.74 $60,751 - $119,041	15,380 Added 1.29%	1,209,380 $9.03 Million
Q1 2023 May 12, 2023	BUY	$3.56 - $5.22 $1.06 Million - $1.55 Million	297,400 Added 33.17%	1,194,000 $4.73 Million
Q4 2022 Feb 10, 2023	BUY	$3.21 - $5.74 $2.49 Million - $4.45 Million	775,585 Added 640.9%	896,600 $3.21 Million
Q3 2022 Nov 14, 2022	BUY	$4.14 - $22.13 $501,002 - $2.68 Million	121,015 New	121,015 $609,000

1.8M

14.7K

Ticker MOR
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 136,614,000
Description
MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, f...

Get notified when there are updates to the investment portfolio of Opaleye Management Inc., based on Form 13F filings with the SEC.

Stay updated on Opaleye Management Inc. with notifications on news.